Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs

US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.

Manufacturer Participation In Scheme Is Voluntary, But PBMs Would Have No Choice • Source: Shutterstock

A new US Senate bill to lower insulin costs co-authored by Sens. Jeanne Shaheen, D-NH, and Susan Collins, R-ME, takes a comprehensive approach to addressing the problem by seeking to lower list prices in addition to limiting patient cost sharing.

It builds on an earlier bill sponsored by Sen. Raphael Warnock, D-GA, and other Democrats that would require Medicare Part...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access